Clinical Trial Update: Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) [Phase 3]

View source ↗

Summary

This Phase 3 trial (ALPHABET) assesses adding Alpelisib to Trastuzumab with or without Fulvestrant versus Trastuzumab plus chemotherapy in patients with PIK3CA-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Alpelisib (alpelisib)
• Chemotherapy (chemotherapy)
• Fulvestrant (fulvestrant)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Spanish Breast Cancer Research Group | Conditions: Advanced Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING